Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring childhood infratentorial ependymoma, childhood supratentorial ependymoma, localized resectable neuroblastoma, regional neuroblastoma, disseminated neuroblastoma, stage 4S neuroblastoma, extraocular retinoblastoma, childhood choroid plexus tumor, localized unresectable neuroblastoma, previously untreated childhood rhabdomyosarcoma, untreated childhood supratentorial primitive neuroectodermal tumor, untreated childhood medulloblastoma, newly diagnosed childhood ependymoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed malignant, newly diagnosed brain tumor Regimen A: Posterior fossa medulloblastoma/primitive neuroectodermal tumor (PNET): All stages, under 3 years at diagnosis OR High stage (local residual tumor postoperatively and/or neuraxis or extraneural dissemination), 3-10 years at diagnosis Supratentorial PNET, pineoblastoma, cerebral neuroblastoma, ependymoblastoma, medulloepithelioma, medullomyoblastoma: All stages, under 10 years at diagnosis Brainstem PNET: All stages, irrespective of extent of resection, under 10 years at diagnosis Ependymoma or anaplastic ependymoma: All stages, any location (except primary spinal cord ependymoma), under 3 years at diagnosis OR Local residual tumor postoperatively and/or neuraxis dissemination, any location, 3-10 years at diagnosis Supratentorial ependymoma: All stages, irrespective of extent of resection, under 10 years at diagnosis, excluding gross totally resected (confirmed by postoperative MRI) low grade ependymoma not invading the ventricular system Metastatic retinoblastoma: Previously untreated (except for cryosurgery or laser surgery), under 10 years at presentation of metastatic disease Primary atypical teratoid/rhabdoid tumors of the CNS: Under 10 years at diagnosis Choroid plexus carcinoma: Incompletely resected, all sites, under 10 years at diagnosis Regimen C: Anaplastic astrocytoma, glioblastoma multiforme, anaplastic oligodendroglioma, anaplastic ganglioglioma, other anaplastic mixed gliomas: Under 10 years at diagnosis Diffuse intrinsic pontine tumors: Unbiopsied, under 10 years at diagnosis The following diagnoses are not eligible: Myxopapillary ependymoma of the spinal cord, low grade brainstem astrocytoma, primary CNS lymphoma or solid leukemic lesion (i.e., chloroma, granulocytic sarcoma), or primary CNS germ cell tumor PATIENT CHARACTERISTICS: Age: Under 10 at diagnosis Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 mg/dL SGPT less than 2.5 times upper limit of normal Renal: Creatinine clearance greater than 60 mL/min PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Prior corticosteroids allowed No concurrent corticosteroids for the sole purpose of antiemesis Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics Recovered from prior surgery
Sites / Locations
- Cancer Research Center of Hawaii
- Maine Children's Cancer Program
- Spectrum Health and DeVos Children's Hospital
- Children's Hospital of Omaha
- Hackensack University Medical Center
- Albert Einstein Clinical Cancer Center
- Winthrop University Hospital
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
- Memorial Sloan-Kettering Cancer Center
- Herbert Irving Comprehensive Cancer Center
- Beth Israel Hospital North
- State University of New York Health Sciences Center - Stony Brook
- State University of New York - Upstate Medical University
- St. Vincent Mercy Medical Center
- Milton S. Hershey Medical Center
- Children's Hospital of Philadelphia
- University of Wisconsin Comprehensive Cancer Center
- Children's Hospital
- British Columbia Children's Hospital